IDH1 and cholangiocarcinoma: They were approved by the FDA for relapsed or refractory AML with mutant IDH based on phase 1/2 clinical trials and efficacy data, and their effects are still being assessed in other diseases including hematologic malignancies, glioma, cholangiocarcinoma, and chondrosarcoma.